Announcements Trials
Browse Landscape

Phase

Phase NA 2Phase 2 1

Status

Active not recruiting 2Completed 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Conditions

Breast Neoplasms 3099Neoplasms 2443Carcinoma, Non-Small-Cell Lung 1867Prostatic Neoplasms 1619Colorectal Neoplasms 1426Lung Neoplasms 1295Multiple Myeloma 929Neoplasm Metastasis 920Leukemia, Myeloid, Acute 874Pancreatic Neoplasms 848Ovarian Neoplasms 799Melanoma 784Carcinoma, Hepatocellular 737Stomach Neoplasms 639Brain Neoplasms 636Recurrence 633Squamous Cell Carcinoma of Head and Neck 632Head and Neck Neoplasms 609Glioblastoma 567Lymphoma 540Uterine Cervical Neoplasms 539Triple Negative Breast Neoplasms 505Precursor Cell Lymphoblastic Leukemia-Lymphoma 499Carcinoma, Renal Cell 499Hematologic Neoplasms 463Urinary Bladder Neoplasms 459Endometrial Neoplasms 459Colonic Neoplasms 442Lymphoma, Non-Hodgkin 436Sarcoma 434

Interventions

ruxolitinib 1Advance Care Planning 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Other Cancer × 1 year × Clear all
NCT03752268 2026-03-27

Development of an Intervention to Enhance Cancer Pain Management

Massachusetts General Hospital

Phase NA Active not recruiting
150 enrolled

Other Cancer

NCT03674047 2025-11-10

Ruxolitinib for Bronchiolitis Obliterans Syndrome (BOS) After Allogeneic Hematopoietic Cell Transplantation (HCT)

Massachusetts General Hospital

Phase 2 Active not recruiting
50 enrolled

Other Cancer

NCT03609177 2025-10-21

ACP-PEACE

Dana-Farber Cancer Institute

Phase NA Completed
13,800 enrolled 15 charts

Other Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡